📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Hikal Q3 FY26 Revenue at ₹494 Cr; EBITDA Margins Recover to 16.8% Amid Pharma Turnaround
Hikal reported a recovery in Q3 FY26 with consolidated revenue of ₹494 crores and a significantly improved EBITDA margin of 16.8%, driven by the Pharmaceutical segment's return to operational normalcy. The company declared an interim dividend of ₹0.2 per share despite a reported loss caused by a one-time exceptional charge of ₹38 crores related to new labor code provisions. While the Pharma division saw revenue of ₹337 crores, the Crop Protection business at ₹157 crores continues to face pricing headwinds from Chinese overcapacity. Management expects a stronger Q4 as remediation efforts regarding US FDA audits are nearly complete and new capacities become operational.
Key Highlights
Q3 FY26 EBITDA stood at ₹83 crores with margins expanding to 16.8% compared to the 9M average of 9.6%
Pharmaceutical segment revenue reached ₹337 crores with a 12.3% EBIT margin as supply resumed post-remediation
A one-time exceptional charge of ₹38 crores for labor code compliance impacted the bottom line, though adjusted PBT grew 21%
Debt-equity ratio remains stable at 0.58 with ₹100 crore capex spent during the first nine months of FY26
Diversification into Personal Care is underway with 3-4 products expected to commercialize in FY27
💼 Action for Investors
Investors should monitor the sustainability of the Pharma margin recovery and the successful ramp-up of the new specialty chemicals vertical in FY27. The stock is a 'Watch' for consistent execution following the completion of intensive regulatory remediation.
Hikal Declares ₹0.20 Interim Dividend; Sets Feb 17, 2026 as Record Date
Hikal Limited has declared an interim dividend of ₹0.20 per equity share (10% of face value) for the financial year 2025-26. The company has fixed February 17, 2026, as the record date to identify eligible shareholders, with the dividend payment scheduled to be completed by March 12, 2026. Investors are required to submit necessary tax documentation by February 18, 2026, to ensure appropriate Tax Deduction at Source (TDS) rates are applied. The standard TDS rate for resident shareholders with a valid PAN is 10%, provided the dividend exceeds ₹10,000.
Key Highlights
Interim dividend of ₹0.20 per equity share (10% on face value of ₹2) for FY 2025-26.
Record date for dividend eligibility is fixed as February 17, 2026.
Dividend payment to be processed on or before March 12, 2026.
TDS of 10% for residents with PAN; 20% for those without valid PAN or non-residents without treaty benefits.
Deadline for submitting tax exemption forms (15G/15H/TRC) is February 18, 2026.
💼 Action for Investors
Investors should ensure their PAN and bank account details are updated with their Depository Participant by February 17. To avoid higher tax withholding, eligible shareholders must submit Form 15G/15H or Tax Residency Certificates to the company by the February 18 deadline.
Hikal Limited Sets February 17, 2026, as Record Date for Interim Dividend
Hikal Limited has announced Tuesday, February 17, 2026, as the record date for determining shareholder eligibility for an interim dividend for the financial year 2025-26. The decision was finalized during a board meeting held on February 11, 2026. This corporate action confirms the company's intent to distribute profits to its shareholders for the current fiscal year. Investors must hold the company's equity shares in their demat accounts by this date to qualify for the payout.
Key Highlights
Record date for interim dividend fixed as February 17, 2026
Dividend pertains to the Financial Year 2025-26
Board approval for the dividend was granted on February 11, 2026
Applicable for equity shareholders on both BSE (524735) and NSE (HIKAL)
💼 Action for Investors
Investors seeking to receive the dividend should ensure they own the stock before the ex-dividend date, typically one business day prior to the record date. Existing shareholders should maintain their holdings through the record date to remain eligible.
Hikal Q3 FY26: Revenue Up 10% to ₹494 Cr, EBITDA Up 15%; 10% Interim Dividend Declared
Hikal reported a 10% YoY revenue growth to ₹494 crore in Q3 FY26, driven by a recovery in the Pharmaceutical segment which grew to ₹337 crore. EBITDA increased by 15% to ₹83 crore with margins expanding by 70 bps to 16.8%, despite an exceptional charge of ₹38 crore for labor code implementation. The company has substantially completed US FDA remediation measures and expects a strong Q4 performance. The board also approved a 10% interim dividend, reflecting confidence in the recovery phase.
Key Highlights
Consolidated Revenue grew 10% YoY to ₹494 Cr, while EBITDA rose 15% to ₹83 Cr.
EBITDA margins improved by 70 bps YoY to 16.8% due to operational efficiencies.
Pharmaceutical segment revenue rebounded to ₹337 Cr as supply deferrals from H1 were addressed.
Exceptional item of ₹38 Cr recorded for the implementation of the new Labour Code.
Interim dividend of 10% of Face Value approved by the Board.
💼 Action for Investors
Investors should monitor the final resolution of US FDA regulatory status and the ramp-up of the new Personal Care segment. The improving debt-equity ratio of 0.58x and margin recovery signal a healthy turnaround.
Hikal Q3 FY26: Revenue Rebounds 55% QoQ to ₹494 Cr; Pharma Recovery Underway
Hikal reported a strong sequential recovery in Q3 FY26 with revenue reaching ₹494 crore, a 55% increase over Q2 FY26, driven by the resumption of supplies in the Pharmaceutical segment following regulatory remediation. EBITDA grew 15% YoY to ₹83 crore, though the bottom line was impacted by a ₹38 crore exceptional charge related to the new labor code, resulting in a net loss of ₹6 crore. The Pharmaceutical division saw a significant rebound with ₹337 crore in revenue, while the Crop Protection segment remains under pressure due to global pricing challenges. Management indicates that the foundation for a stronger FY27 is in place with new high-potency labs and pilot plants becoming operational.
Key Highlights
Q3 Revenue grew 55% QoQ to ₹494 crore, signaling a recovery from H1 regulatory deferrals.
Pharmaceutical segment revenue rose to ₹337 crore with an EBIT margin of 12.3% as remediation measures near completion.
EBITDA margins improved significantly to 16.8% in Q3 FY26 compared to 2.4% in the previous quarter.
Recorded a one-time exceptional expense of ₹38 crore due to the implementation of the new labor code.
Balance sheet remains stable with a Debt-Equity ratio of 0.58x and 9M FY26 revenue at ₹1,193 crore.
💼 Action for Investors
Investors should monitor the sustainability of the Pharmaceutical segment's recovery and the successful commercialization of the new Personal Care business in FY27. While the sequential turnaround is positive, the Crop Protection segment's margins remain a point of concern due to Chinese pricing pressure.
Hikal Declares ₹0.20 Interim Dividend Amid Q3 Net Loss and Revenue Recognition Review
Hikal Limited has declared an interim dividend of ₹0.20 per share despite reporting a standalone net loss of ₹59 million for the quarter ended December 2025. The company's financial health is currently under pressure from a ₹380 million exceptional charge related to new labour codes and a USFDA warning letter impacting its Jigani facility. Most significantly, auditors have issued a modified opinion due to an ongoing internal investigation into irregularities regarding the timing of revenue recognition. While revenue for the quarter showed a slight recovery to ₹4,943 million, the nine-month period remains in a loss of ₹633 million.
Key Highlights
Interim dividend of ₹0.20 per equity share (10% of face value) declared with record date of Feb 17, 2026.
Reported a standalone net loss of ₹59 million in Q3 FY26 versus a profit of ₹173 million in the same quarter last year.
Auditors issued a modified opinion citing inability to comment on revenue recognition irregularities pending an internal review.
Recognized an exceptional item of ₹380 million for gratuity and compensated absences following labour code changes.
Pharma segment revenue of ₹3,373 million was impacted by customer deferrals following a USFDA warning letter for the Jigani facility.
💼 Action for Investors
Investors should remain cautious as the auditor's modified opinion and revenue recognition irregularities represent significant governance risks. The impact of the USFDA warning letter and the ongoing Supreme Court environmental litigation further cloud the near-term recovery prospects.
Hikal Q3 Revenue Up 10% to ₹4,943M, Reports Net Loss of ₹59M; Declares ₹0.20 Dividend
Hikal Limited reported a 10.4% year-on-year increase in revenue to ₹4,943 million for Q3 FY26, but posted a net loss of ₹59 million compared to a profit of ₹173 million in the previous year. The bottom line was heavily impacted by a ₹380 million exceptional item related to new Labour Codes and a change in the company's gratuity policy. Operational performance in the Pharma segment was hindered by a USFDA warning letter for the Jigani facility, leading to deferred customer purchases. Despite the loss, the company declared an interim dividend of ₹0.20 per share.
Key Highlights
Revenue from operations grew 10.4% YoY to ₹4,943 million, with the Pharma segment contributing ₹3,373 million.
Reported a net loss of ₹59 million for the quarter, largely due to a ₹380 million exceptional charge for employee benefits and labour code compliance.
Statutory auditors issued a modified opinion citing ongoing investigations into irregularities regarding the timing of revenue recognition.
Pharma segment sales were adversely impacted by a USFDA warning letter issued in August 2025 for the Jigani facility.
Declared an interim dividend of ₹0.20 per equity share (10% of face value) with a record date of February 17, 2026.
💼 Action for Investors
Investors should exercise caution given the auditor's qualification on revenue recognition and the regulatory challenges from the USFDA. The stock remains under watch until there is more clarity on the internal fact-finding review and the resolution of environmental litigation in the Supreme Court.
Hikal Reports Employee Misconduct in Revenue Recognition; Reverses ₹80.7 Cr Revenue
Hikal Limited has disclosed irregularities by employees in Sales, Marketing, and Logistics regarding revenue recognition and documentation. The company has already reversed ₹80.7 crore in revenue for Q2FY26 and noted that sales in Q4FY25 and Q1FY26 were inflated by approximately 2% due to these alterations. While the company clarifies that all underlying sales are genuine and no funds were siphoned or embezzled, the timing of revenue recognition was manipulated. This discovery follows a fact-finding review, and the company is now evaluating legal reporting requirements to authorities.
Key Highlights
Identified irregularities in revenue recognition and documentation across Q4FY25, Q1FY26, and Q2FY26.
Reversed ₹80.7 crore of revenue for the Q2FY26 period following an internal fact-finding review.
Sales for Q4FY25 and Q1FY26 were approximately 2% higher than actuals due to employee misconduct.
Management confirms no siphoning or embezzlement of funds; all sales are backed by genuine Customer Purchase Orders.
Misconduct involved employees in Sales & Marketing, Logistics, and allied operational functions.
💼 Action for Investors
Investors should exercise caution as this highlights significant internal control weaknesses, despite the lack of fund misappropriation. Monitor for potential restatements of past financial results and any further regulatory actions or penalties.